Codexis, Inc. Common Stock CDXS
i
Market datapartial · fetched 2026-11-07T08:10:14.467Z
Delta surfaceAlpaca · derived absolute-delta buckets ·
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T22:08:43.578141268Z
FundamentalsAlpha Vantage · unavailable
Codexis, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | ||||||
| 45Δ | ||||||
| 50Δ | ||||||
| 55Δ | ||||||
| 60Δ | ||||||
| 65Δ | ||||||
| 70Δ | ||||||
| 75Δ | ||||||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 213.46% | |
| 269.78% | |
| 231.42% | |
| 235.33% | |
| 242.52% | |
| 239.03% | |
| 259.17% | |
| 279.96% | |
| 274.82% | |
| 309.32% |
Biotechnology
CELC
Celcuity Inc., a clinical-stage biotechnology company, discovers cancer subtypes and therapeutic options for cancer patients in the United States. The company is headquartered in…
More →CELU
Celularity Inc. is a pioneering biotechnology company focused on regenerative medicine through its innovative cellular products derived from the placenta. The company is advancing…
More →CGEM
Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients in the United…
More →CGON
CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing groundbreaking cancer therapies, particularly through its lead product, CG0070, an oncolytic virus…
More →CHRS
Description unavailable
More →CING
Description unavailable
More →